|
Model Number TVTRL |
Device Problem
Migration (4003)
|
Patient Problem
Erosion (1750)
|
Event Date 04/01/2022 |
Event Type
Injury
|
Event Description
|
It was reported that a patient underwent a gynecological procedure on (b)(6) 2021 and mesh was implanted.On (b)(6) 2022, mesh erosion was noted.The patient received unspecified drug therapy.The erosion has been reported as a causal relationship with the study procedure, but not related to the study device.The event has been recovered/resolved without sequelae as of (b)(6) 2022.Additional information was requested.
|
|
Manufacturer Narrative
|
(b)(4).This report is being submitted pursuant to the provisions of 21 cfr, part 803.This report may be based on information which has not been investigated or verified prior to the required reporting date.This report does not reflect a conclusion by ethicon inc, or its employees that the report constitutes an admission that the product, ethicon inc, or its employees caused or contributed to the potential event described in this report.If information is obtained that was not available for the initial report, a follow-up report will be filed as appropriate.Attempts are being made to obtain the following information.To date no response has been provided.If further details are received at a later date a supplemental medwatch will be sent.Please provide the site/location, symptoms and diagnostic confirmation of the mesh erosion noted on (b)(6) 2022.Describe the drug therapy provided for this mesh erosion including medication name and results.Was any surgical intervention performed? if so, please provide the date and findings.What is the physician¿s opinion as to the etiology of or contributing factors to this event? what is the patient's current status? to date it has been reported that the device will not be returned.If the device or further details are received at a later date a supplemental medwatch will be sent.(b)(4).A manufacturing record evaluation was performed for the finished device batch, and no non-conformances were identified.Related events captured via 2210968-2022-09423.
|
|
Manufacturer Narrative
|
(b)(4) this report is being submitted pursuant to the provisions of 21 cfr, part 803.This report may be based on information which has not been investigated or verified prior to the required reporting date.This report does not reflect a conclusion by ethicon inc, or its employees that the report constitutes an admission that the product, ethicon inc, or its employees caused or contributed to the potential event described in this report.If information is obtained that was not available for the initial report, a follow-up report will be filed as appropriate.Additional information was requested and the following was received: please provide the site/location, symptoms and diagnostic confirmation of the mesh erosion noted on 05/06/2022: patient had no symptoms, mesh erosion was detected by a speculum describe the drug therapy provided for this mesh erosion including medication name and results: patient had no therapy from (b)(6)2022 until (b)(6)2022.Local estrogenization was recommended using ovestin creme 1mg from (b)(6)2022 till (b)(6)2022 (once a day).Was any surgical intervention performed? if so, please provide the date and findings: no.What is the physician¿s opinion as to the etiology of or contributing factors to this event? lack of estrogenization of the vaginal epithelium and increased physical exercises what is the patient's current status?: patient has no complaints.Related events captured via 2210968-2022-07212 and 2210968-2022-09423.
|
|
Search Alerts/Recalls
|
|
|